AzTrials
AzTrials

Condition

Covid19 Clinical Trials

Studies of covid19, matched by condition name and medical subject headings. Start with those open to enrolment.

10,266 registered studies

In numbers

Open to volunteers
438
Active
667
With results posted
1,092
All registered
10,266

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 438
  • SARS-CoV-2

    A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

    • Recruiting
    • Age: 12 years and older
    • Phase 3

    The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.

    Trial name
    NCT07743580
    Testing
    Secutrelvir
    Where
    47 sites in United States, Bulgaria and 1 more
    Volunteers
    2,000 people
    Sponsor
    Shionogi
    Can I take part? NCT07743580
  • Anogenital Herpes, COVID-19

    Viral Infections in Healthy and Immunocompromised Hosts

    • Recruiting
    • Age: 6 months to 120 years
    • Observational study

    Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.

    Conditions
    Anogenital Herpes, COVID-19, Herpes Labialis
    Trial name
    NCT01306084
    Where
    United States
    Volunteers
    1,000 people, healthy volunteers welcome
    Sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
    Can I take part? NCT01306084
  • Post-Acute COVID-19 Syndrome

    Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    • Not yet recruiting
    • Age: 18 to 110 years
    • Phase 1

    Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years.

    Trial name
    NCT07388550
    Testing
    Keytruda
    Where
    United States
    Volunteers
    15 people
    Sponsor
    National Institute of Neurological Disorders and Stroke (NINDS)
    Can I take part? NCT07388550
  • COVID 19, Influenza

    COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

    • Recruiting
    • Age: 18 years and older
    • Phase 2
    • Vaccines

    The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…

    Conditions
    COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
    Trial name
    CO2I2 (NCT06599658)
    Testing
    Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
    Where
    3 sites in Canada
    Volunteers
    660 people
    Sponsor
    McGill University Health Centre/Research Institute of the McGill University Health Centre
    Can I take part? CO2I2
  • COVID-19 Respiratory Infection, Influenza

    Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

    • Recruiting
    • Age: 18 years and older
    • Medical device

    The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld…

    Trial name
    LIGHT (NCT07610967)
    Testing
    RD-X19
    Where
    United States
    Volunteers
    130 people, healthy volunteers welcome
    Sponsor
    David Moss
    Can I take part? LIGHT
  • Systemic Inflammation, Neuroinflammation

    Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    • Enrolling by invitation
    • Age: 18 to 100 years
    • Phase 2
    • Injection or infusion

    Background: COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way.

    Conditions
    Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
    Trial name
    NCT05350774
    Testing
    IV normal saline, IV immunoglobulin
    Where
    United States
    Volunteers
    45 people
    Sponsor
    National Institute of Neurological Disorders and Stroke (NINDS)
    Can I take part? NCT05350774
  • Long COVID

    DAOIB for the Treatment of Brain Fog

    • Recruiting
    • Age: 18 to 100 years
    • Phase 2

    This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.

    Trial name
    NCT05764538
    Testing
    DAOIB
    Where
    Taiwan
    Volunteers
    40 people
    Sponsor
    Chang Gung Memorial Hospital
    Can I take part? NCT05764538
  • Respiratory Viral Infections, Influenza

    Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections

    • Not yet recruiting
    • Age: 18 years and older

    The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared…

    Conditions
    Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
    Trial name
    NCT07892872
    Testing
    Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations
    Where
    China
    Volunteers
    618 people
    Sponsor
    Capital Medical University
    Can I take part? NCT07892872
  • COVID-19

    A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

    • Recruiting
    • Age: 18 to 64 years
    • Phase 1

    This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a…

    Trial name
    NCT07536308
    Testing
    OCU500
    Where
    6 sites in United States
    Volunteers
    80 people, healthy volunteers welcome
    Sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
    Can I take part? NCT07536308
  • Post-Coronavirus Disease 19

    Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

    • Recruiting
    • Age: 18 to 100 years
    • Observational study

    Background: People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover…

    Trial name
    NCT04573062
    Where
    United States
    Volunteers
    1,590 people
    Sponsor
    National Institute of Neurological Disorders and Stroke (NINDS)
    Can I take part? NCT04573062

Completed, with results posted

All 849
  • Sepsis, Pneumonia

    Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia

    • Completed
    • Age: 21 years and older
    • Lifestyle or therapy programme
    • Results posted

    An adaptive platform trial to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or lower respiratory tract infection.

    Conditions
    Sepsis, Pneumonia, Lower Resp Tract Infection, Covid19
    Trial name
    ACCOMPLISH (NCT04829188)
    Testing
    Structured Telephone Support (STS), Low-intensity Remote Patient Monitoring (RPM-Low), High-intensity Remote Patient Monitoring (RPM-High)
    Where
    United States
    Volunteers
    1,296 people
    Sponsor
    University of Pittsburgh
    Can I take part? ACCOMPLISH
  • Sars-CoV2, Acute Respiratory Distress Syndrome

    Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

    • Completed
    • Age: 18 years and older
    • Phase 1/2
    • Results posted

    *At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.* This is a study for patients who have respiratory infection caused by…

    Conditions
    Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
    Trial name
    NCT04345601
    Testing
    Mesenchymal Stromal Cells, Supportive Care
    Where
    United States
    Volunteers
    28 people
    Sponsor
    Baylor College of Medicine
    Can I take part? NCT04345601
  • Birth Outcomes, Safety

    Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

    • Completed
    • Age: 18 years and older
    • Phase 4
    • Vaccines
    • Results posted

    This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart).

    Conditions
    Birth Outcomes, Safety, Adverse Event Following Immunization
    Trial name
    NCT06503900
    Testing
    mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
    Where
    6 sites in United States
    Volunteers
    98 people, healthy volunteers welcome
    Sponsor
    Duke University
  • Long COVID

    Fluvoxamine for Long COVID-19

    • Completed
    • Age: 25 years and older
    • Phase 2/3
    • Results posted

    This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in…

    Trial name
    NCT05874037
    Testing
    Fluvoxamine
    Where
    United States
    Volunteers
    191 people
    Sponsor
    Washington University School of Medicine
  • SARS-CoV-2 Infection

    Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

    • Completed
    • Age: All ages
    • Phase 3
    • Results posted

    The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test)…

    Trial name
    SCORPIO-PEP (NCT05897541)
    Testing
    S-217622
    Where
    178 sites in United States, Argentina and 3 more
    Volunteers
    3,701 people, healthy volunteers welcome
    Sponsor
    Shionogi

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in